Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print

Topics - Drug Development


Refine by Date:
From: To:
Published September 29, 2014
Expands gene-editing capabilities Read More »
Published September 29, 2014
Gains Phase III AML candidate quizartinib Read More »
Published September 29, 2014
Expands therapeutic offerings and Asia-Pac reach Read More »
Published September 24, 2014
Baxter gains ex-U.S. rights to Phase III, orphan pancreatic cancer drug Read More »
Published September 24, 2014
Aims to develop a gene therapy to treat rare genetic disease Read More »
Published September 23, 2014
Aims to address unmet medical needs Read More »
Published September 22, 2014
Boehringer will conduct trials in advanced and unresectable NSCLC Read More »
Published September 22, 2014
Silarus Therapeutics and Thyritope Biosciences will receive $10M in financing and R&D support Read More »
Published September 16, 2014
Gains exclusive rights to develop and commercialize products globally Read More »
Published September 16, 2014
To co-develop and commercialize BACE inhibitor, AZD3293 Read More »
Published September 12, 2014
Will leverage Evotec's high-throughput screening and proteomics platforms Read More »
Published September 12, 2014
Aims to meet clinical development needs for all therapeutic areas Read More »
Published September 11, 2014
Additional funding to support Phase II trial of CLT-008 in AML Read More »
Published September 11, 2014
Will use MabVax platform to develop anti-cancer therapeutics Read More »
Published September 10, 2014
Genmab to pay $11 million for exclusive rights to Seattle Genetics' ADC technology Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On